Twin Cities, MN— November 30th, 2022 — Biomedix, a market-leading medical technology and innovation company, announced that the PADnet Xpress device has received clearance from the FDA for use in the home.
“We are excited to announce the expanded clearance for in-home use of PADnet Xpress,” said John Romans, CEO of Biomedix. “With almost 20% of the US population living in rural areas, delivering care to those who may lack reliable transportation to their nearest clinic is critical.”
“At Biomedix, we make patient safety a priority,” said Chris Trygstad, Marketing and Network Director at Biomedix. “Considering the changing healthcare landscape where care is being delivered in non-traditional environments, we invested the time and resources to ensure providers had the technology to safely and accurately identify PAD in patients’ homes.”
About Biomedix
Biomedix is a provider of point-of-care diagnostic solutions for delivering value-based care. Biomedix Xchange is a population health solution that centralizes data for analyzing population health across multiple chronic conditions. For more information, visit Biomedix.com.
About PADnet & PADnet Xpress
Biomedix is the maker of PADnet, the market leader in front-line diagnostics for peripheral vascular disease. PADnet is the only diagnostic device that can support the identification of PAD and chronic venous insufficiency (CVI) through a unique collaborative care model. PADnet Xpress represents the latest technology for quick and accurate PAD detection, custom-designed for value-based care, including Medicare Advantage Organizations (MAOs).
